Navigation Links
BioSeek Initiates Systems Biology Compound Evaluation Collaboration with UCB
Date:12/5/2007

BURLINGAME, Calif., Dec. 5 /PRNewswire/ -- BioSeek, Inc., a leader in applying integrated human biology systems for developing new therapeutics, announced today that it has entered into a collaboration agreement with UCB, a global biopharmaceutical leader based in Belgium. Under the collaboration, BioSeek will apply its BioMAP(R) Systems to evaluate a number of UCB compounds across several target classes, in support of target differentiation, lead development, and drug candidate selection activities at UCB.

"We are excited to be working closely with UCB, an innovative biopharmaceutical company combining distinctive strengths in chemistry and biology, and focusing on severe diseases in three important therapeutic areas, CNS, inflammation and oncology," commented Michael C. Venuti, Ph.D., CEO of BioSeek. "This collaboration leverages the power of our systems biology technology across multiple disease areas and multiple phases of the drug development process."

"The BioMAP(R) platform represents a very promising approach to applying the promise of whole-systems biology to the drug discovery and development process," stated Dr. Mark Bushfield, VP, NCE Research, UCB.

BioSeek's BioMAP(R) Systems are a series of human primary cell-based assay systems designed to replicate the intricate cell and pathway interactions present in human disease biology. Depending on their mechanism of action, compounds induce specific patterns of changes in these systems (BioMAP profiles) that can be compared to a large number of reference profiles in BioSeek's database. BioMAP profiling can provide in-depth characterization of drug function, including defining mechanism of action and secondary activities, and can provide insights into potential clinical applications. In addition to characterizing previously identified lead compounds, BioSeek is using BioMAP Systems for primary screening, to rapidly generate lead compounds that have novel activity in a particular disease setting.

About BioSeek

BioSeek is improving the success rate of pharmaceutical research and development by integrating human biology from the early stages of drug discovery onward. The Company's BioMAP(R) Systems incorporate predictive human cell-based disease models that generate uniquely informative activity signatures for each potential drug, driving the selection and development of new drug candidates. BioSeek is leveraging BioMAP(R) Systems technology in collaborations to enhance the productivity of its pharmaceutical partners' pipelines, and in the Company's internal programs to identify promising compounds for proprietary development in the fields of inflammation, cardiovascular diseases, autoimmune diseases, and related indications.

For more information, go to http://www.bioseekinc.com

About UCB

UCB, Brussels, Belgium (http://www.ucb-group.com) is a global leader in the biopharmaceutical industry dedicated to the research, development and commercialisation of innovative pharmaceutical and biotechnology products in the fields of central nervous system disorders, allergy/respiratory diseases, immune and inflammatory disorders and oncology. UCB focuses on securing a leading position in severe disease categories. Employing more than 10,000 people in over 40 countries, UCB achieved revenue of 3.5 billion euro in 2006 on a pro forma basis. UCB S.A. is listed on the Euronext Brussels Exchange and, through its affiliate, owns approx. 89% of the shares of SCHWARZ PHARMA AG. SCHWARZ PHARMA (Monheim, Germany) is a member of the UCB Group.

BioSeek Contacts:

BioSeek, Inc.

Michael Venuti, Ph.D.

CEO

Tel: 650.552.0754

MacDougall Biomedical Communications

Jennifer Greenleaf

Tel: 781.235.3060


'/>"/>
SOURCE BioSeek, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. BioSeek Appoints Michael C. Venuti, Ph.D., Chief Executive Officer
2. Tyco International Increases Quarterly Dividend 36 Percent to 15 Cents per Share; Initiates New $1 Billion Share Repurchase Program
3. Chemical Diversity Initiates International Prostrate Cancer Discovery Partnership
4. Vista Partners Initiates Coverage on Raptor Pharmaceuticals Corp.
5. Arete Therapeutics Initiates Phase 1 Clinical Trial For AR9281 as a First-in-Class Antihypertensive Agent
6. GenPrime Initiates External Clinical Trials of its Bacterial Contamination Test for Rapid Detection of Bacteria in Platelets
7. U.S. Oncology Initiates Complete Phase Ib Trial of Brostallicin Combination Therapy in Advanced Solid Tumors
8. Harbinger Research Initiates Coverage on HearAtLast
9. Wyeth Consumer Healthcare Initiates Voluntary Recall and Replacement Program for Several Robitussin Products and Childrens Dimetapp Cold & Chest Congestion
10. MAP Pharmaceuticals Initiates Phase 2a Clinical Trial of Combination Therapy in Adult Patients with Asthma
11. Amira Pharmaceuticals Announces Favorable Phase 1 Clinical Trial Results for Lead Product Candidate AM103 and Initiates Clinical Studies for the 2nd Entry Molecule for the Treatment of Respiratory and Cardiovascular Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/20/2017)... , ... June 20, 2017 , ... ... contending that the introduction of school choice can promote economic development in economically ... school that has, according to the report, contributed to the economic development of ...
(Date:6/20/2017)... ... June 20, 2017 , ... AMC Health , the ... success in the clinical trials market. Similar to its approach in demonstrating positive outcomes ... clinical trials marketplace by proving the value of eVisits to support virtual studies. ...
(Date:6/20/2017)... ... ... Leading dental clinicians, Drs. Ashlyn Price, Autumn Mayers and Ron Adelman, now offer ... advanced digital images and modeling capabilities, the dentists identify all of the structures in ... for those who are missing teeth in Midlothian, VA. , In the ...
(Date:6/20/2017)... ... ... As a leading dental practice, Wall Centre Dental supports Stroke Awareness Month ... bleeding gums in Vancouver, BC, may be developing gingivitis, the first stage of ... and diabetes. Drs. Parviz Roshan, Siamak Tehrani and Milton Reskovich offer laser gum therapy ...
(Date:6/20/2017)... ... June 20, 2017 , ... ... (AHN) Jefferson Hospital is providing physicians with advanced capabilities for diagnosing and treating ... than traditional MRIs, enabling doctors to get a more accurate look inside the ...
Breaking Medicine News(10 mins):
(Date:6/7/2017)... -- Novavax, Inc., (Nasdaq: NVAX ) today announced that ... its RSV F protein recombinant nanoparticle vaccine candidate (RSV F ... in the journal Vaccine (the data ... conferences). The Company previously announced top line results ... RSV F Vaccine with the goal of protecting infants from ...
(Date:6/3/2017)...  Eli Lilly and Company (NYSE: ... Phase 3 MONARCH 2 study showed that abemaciclib, ... combination with fulvestrant, significantly improved progression-free survival (PFS) ... with hormone-receptor-positive (HR+), human epidermal growth factor receptor ... or progressed after endocrine therapy (median PFS, 16.4 ...
(Date:5/30/2017)... May 30, 2017 Hill-Rom Holdings, Inc. (NYSE: HRC), ... Global Healthcare Conference on Tuesday, June 13, 2017, in ... , Hill-Rom,s president and chief executive officer, is scheduled to ... audio webcast can be accessed at http://ir.hill-rom.com/events.cfm . A ... the live event through September 13, 2017. ...
Breaking Medicine Technology: